Is Johnson and Johnson Stock a Buy?
Johnson & Johnson (NYSE: JNJ) is a big name in the healthcare industry that has produced stable and consistent returns for investors over the years. It also pays a growing dividend yield. But on the flip side, the company's run into a series of problems over time relating to some of its products.
While J&J's been able to handle the adversity thus far, the inevitable question that comes up is whether these problems could get worse and ultimately have a more adverse effect on the company's financials. As good of an investment as J&J has been over the years, investors may be wondering if it's still worth the risk. Let's have a closer look and assess whether the stock belongs in your portfolio today.
In each of the past 10 quarters, J&J's recorded revenue of at least $20 billion. During that time, only twice has its profit margin been less than 14%. The healthcare giant's been a great model of consistency in recent years. But as impressive as that is, it's the company's legal woes that have been making the headlines.
Source Fool.com
